Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chemomab Therapeutics Ltd ADR (NQ: CMMB )

1.480 -0.090 (-5.73%)
Streaming Delayed Price Updated: 3:38 PM EDT, Oct 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 102,223
Open 1.670
Bid (Size) 1.480 (10)
Ask (Size) 1.500 (1)
Prev. Close 1.570
Today's Range 1.450 - 1.670
52wk Range 0.4200 - 2.550
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Chemomab Therapeutics to Present at October 2024 Investor Conferences
From Chemomab Therapeutics
Via GlobeNewswire
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga

Performance

YTD
+175.20%
+175.20%
1 Month
-39.84%
-39.84%
3 Month
+53.21%
+53.21%
6 Month
+91.91%
+91.91%
1 Year
+66.29%
+66.29%

More News

Read More
Chemomab Therapeutics to Present at September 2024 Investor Conferences
From Chemomab Therapeutics
Via GlobeNewswire
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024
Via InvestorPlace
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise
Via Benzinga
Chemomab Therapeutics Announces $10 Million Private Placement
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
From Chemomab Therapeutics
Via GlobeNewswire
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024
Via InvestorPlace
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
From Chemomab Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
From Chemomab Therapeutics
Via GlobeNewswire
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
From Chemomab Therapeutics
Via GlobeNewswire
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023
Via InvestorPlace
Earnings Scheduled For March 7, 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.